Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desvenlafaxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 9/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | CNR1 | P21554 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | HRH1 | P35367 | 1/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10772550 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL34863 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL3277527 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Hydrochloric Acid SCHEMBL10772551 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL2053955 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL623709 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Hydrochloric Acid SCHEMBL10491682 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL3345158 | 0.98 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL4306707 | 0.97 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3OPRM1LMNA | |
| Desvenlafaxine SCHEMBL4306704 | 0.97 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3OPRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7300 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4727538-A2 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260102372-A1 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2026-04-16 | — | — | US | claimed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260083709-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | APNIMED INC DELAWARE (US) | 2026-03-26 | — | — | US | claimed |
| EP-4687805-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP Technologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20010012855-A1 | New treatment using venlafaxine | WYETH | 2001-08-09 | — | — | US | claimed |
| WO-2000076955-A1 | ENANTIOMERS OF O-DESMETHYL VENLAFAXINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-21 | — | — | WO | claimed |
| EP-0723779-A1 | Medicament for treatment of hypothalamic amenorrhea | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-07-31 | — | — | EP | claimed |
| US-5530013-A | Venlafaxine in the inducement of cognition enhancement | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-06-25 | — | — | US | claimed |
| US-5506270-A | Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-09 | — | — | US | claimed |
| EP-0667150-A1 | Venlamafaxine and its analogues for inducing cognition enhancement | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| EP-0639374-A2 | New treatments using phenethyl derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-02-22 | — | — | EP | claimed |
| EP-0112669-B1 | PHENETHYLAMINE DERIVATIVES AND INTERMEDIATES THEREFOR | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-07-29 | — | — | EP | claimed |
| US-4535186-A | CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS; VENLAFAXINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-08-13 | — | — | US | claimed |
| EP-0112669-A2 | Phenethylamine derivatives and intermediates therefor | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-07-04 | — | — | EP | claimed |